Scholars Central

Conference abstractPublished 2016

Gut microbiota modulates cisplatin mediated systemic toxicity

Authors: Soumen Roy, Rodrigo Das Neves, Carolyne Smith, Bathai Edwards, Amiran Dzutsev, Loretta Smith, Simone Difilippantonio, Lake Ross, Susan Garfield, Poonam Mannan, Lim Langston, Hawes Misty, Ren Ming Dai, Sharon Bargo, Young Kim, Giorgio Trinchieri

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Anticancer chemotherapy has achieved a significant milestone in increasing the number of cancer survivors over past decades, while leaving behind the survivors with various toxic side effects, which are nephrotoxicity, ototoxicity and intestinal damage. Challenges remain to reduce systemic toxicity as well as retaining the anticancer therapy. Gut microbiota modulates cancer chemotherapy, however little is known about the role of gut microbiota in modulating systemic toxicity. We hypothesized that gut microbiota regulates systemic toxicity. Four groups (n=10/group) of 8 weeks old C57B/6 mice were treated with cisplatin, cisplatin+antibiotics cocktails (ABX), ABX only and untreated. ABX cocktail contained primaxin, vancomycin and neomycin, which depletes broad spectrum gut microbiota. This experiment was validated using C57B/6 germ free mice (contains no microorganisms). We performed anti-p-Ã?³-H2AX and anti-ATM based DNA-double stranded break (stains foci in the nuclei) based toxicity assay in kidney and gut (small bowel). H&E and 4 color immunostaining (anti-p-Ã?³-H2AX, anti-ATM, Actin and DAPI) were done. DNA-DSBs were evaluated using Zeiss 780 confocal and quantified by 3-D reconstruction using IMARIS. There were reductions in Ã?³-H2AX+ DAPI+ (DNA damaged) cell populations compared to only cisplatin treated mice, indicated protection in the kidney. Both nuclear foci counts as well as the pathological scores indicated gut microbiota associated modulation in the glomeruli of kidney and in the villi of small bowel. Our data leads to a possibility to develop microbiota based therapy which might be utilized to reduce chemotherapy associated systemic toxicity and for better management of chemotherapy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Oncology & Cancer Case Reports.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalOncology & Cancer Case Reports
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Soumen Roy”
  • BylineArticles whose byline prints “Rodrigo Das Neves”
  • BylineArticles whose byline prints “Carolyne Smith”
  • BylineArticles whose byline prints “Bathai Edwards”
  • BylineArticles whose byline prints “Amiran Dzutsev”
  • BylineArticles whose byline prints “Loretta Smith”
  • BylineArticles whose byline prints “Simone Difilippantonio”
  • BylineArticles whose byline prints “Lake Ross”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels